Summary

Eight adult patients with acute transient arthritis of the hip are described. Follow-up periods varied from 9 to 54 months; average, 24 months.

It is important to exclude acute bacterial arthritis by aspiration of the hip joint.

Two patients are diagnosed confidently, and one provisionally, as cases of rheumatoid arthritis. One patient is diagnosed as a case of rheumatoid arthritis (palindromic) and one as "palindromic rheumatism." One patient possibly suffered from Reiter's syndrome. As yet two patients remain undiagnosed.

We thank Dr. R. M. Mason for kindly reading this paper and for several helpful suggestions.

A FATAL CASE OF PROGRESSIVE VACCINIA

BY

J. H. CONNOLLY, M.D.
G. W. A. DICK, M.D., D.Sc., F.R.C.P.Ed., M.R.C.P.
Department of Microbiology, Queen's University of Belfast

AND

C. M. B. FIELD, M.D., M.R.C.P.Ed., D.C.H.
Belfast City Hospital

Progressive vaccinia (vaccinia necrosum, vaccinia gangrenosa) is a rare complication of vaccination which has recently been reviewed by Kempe (1960) and by Erichson and McNamara (1961). The present case is reported because of the failure of passively transferred antibody or N-methylisatin β-thiosemicarbazone (compound 33T57) to influence the course of the disease.

Case History

The patient, the second child of healthy parents (whose first baby had died soon after birth with a spina bifida), was vaccinated against smallpox by multiple pressure over the left deltoid region at the age of 10 months. The primary vaccination began to develop normally, but at about the same time a papule appeared on the sole of her left foot, which, like the primary lesion, became vesicular in six days. These vesicles increased in size, and when we saw the child four months after vaccination the posterior half of the sole of the left foot was covered by a crusted lesion which extended on to the lateral side and also medially as far as the malleolus. The edge of this lesion was vesiculated and surrounded by a reddish areola. On the outer side of the left arm there was an irregular lesion 5 cm. in diameter with an extension towards the shoulder consisting of raw and crusted areas with a rolled vesicular edge and a surrounding wide zone of erythema (Fig. 1).

Vaccinia virus was recovered from the lesions on the arm and the foot. The child's serum taken at this time contained no demonstrable neutralizing or haemagglutination-inhibiting antibody to vaccinia virus. The serum gammaglobulin was 0.51 g./100 ml., calculated from paper electrophoresis of the serum (Oberman, Gregory, Burke, Ross, and Rice, 1956). Examination of the blood cells showed a hypochromic anaemia (Hb 6.6 g./100 ml.) of the hypoplastic type and a lymphopenia.

Treatment

The treatment of vaccinal complications with gammaglobulin or immune serum has been discussed by Kempe (1960). We began treatment of our patient with intramuscular injections of antivaccinial gammaglobulin (batch EPG 101) and a transfusion of fresh whole blood from an immune donor. The antibody levels and the gammaglobulin which developed in the child's serum are shown in Table I.

<p>| Table 1 |</p>
<table>
<thead>
<tr>
<th>Day of Lesions</th>
<th>Procedure</th>
<th>Material Tested</th>
<th>Antibody Titres*</th>
<th>Serum γ-globulin (g./100 ml.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>126</td>
<td>Test</td>
<td>Patient's serum</td>
<td>&lt;5</td>
<td>0.51</td>
</tr>
<tr>
<td>127</td>
<td>1 g. γ-globulin</td>
<td>γ-Globulin</td>
<td>&lt;5</td>
<td>1,000</td>
</tr>
<tr>
<td>128</td>
<td>100 ml. blood</td>
<td>Patient's serum</td>
<td>2</td>
<td>0.55</td>
</tr>
<tr>
<td>130</td>
<td>Test</td>
<td>Donor's γ-Globulin</td>
<td>20</td>
<td>0.78</td>
</tr>
<tr>
<td>131</td>
<td>Test</td>
<td>Patient's serum</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>133</td>
<td>Test</td>
<td>100 ml. blood</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

* The antibody titres are the highest effective dilutions of serum before the addition of virus
† Haemagglutination inhibition, using the method described by Kempe (1956)
‡ Neutralization tests were kindly carried out by Professor A. W. Downie, University of Liverpool.

A small haematoxa occurred on the back of the child's hand where the transfusion needle was placed, and 5,000 units of lyophilized crystalline alpha-chymotrypsin was given orally three times daily for five days to increase the rate of absorption. On the seventh day after the transfusion the child developed a fever of 103° F. (39.4° C), and on the following two days it was 105° F. (40.6° C.), after which it fell to normal. It is not known whether the febrile
reaction was due to the transfused white cells or the alpha-
chymotrypsin, but there was a marked improvement in the baby’s condition after the transfusion, probably due to the 
correction of the anaemia (Hb 10.1 g./100 ml.) and the 
lesions looked drier for a few days. During this febrile 
period the baby developed an urticarial rash on the face 
and body which faded after four days. By the 12th day of 
treatment an H.I. titre of 1:20 and a total gamma-globulin 
of 0.78 g./100 ml. had been obtained in the patient’s serum.
Further injections of 1 g. of antivaccinal gamma-globulin 
were given on the 12th and 15th days. In addition, for 
the first 11 days of treatment pooled serum from four recently 
vaccinated individuals was applied four-hourly to the 
lesions.

Over the next few weeks the lesions on the arm extended 
on to the shoulder and the spreading edge had increased in 
size. The foot lesion, however, had not progressed. Since 
antibody therapy did not seem to be retarding the slow progress 
of the lesions on the shoulder it was decided to try the 
effect of N-methylisatin β-thiosemiacarbzone, which was 
kindly supplied by Dr. D. J. Bauer, of the Wellcome Labora-
tories Tropical Medicine, London. This drug had been 
shown to be effective against vaccinia in mice when given 
(Bauer and Sadler, 1960). However, because of its 
potential toxicity, we decided to try it first as a suspension 
of 10% powder in a cream which was applied four times 
daily to the lesions on the arm. The lesions were now 147 
days old. During the first week of this treatment there was 
no obvious toxicity. Urine samples were normal, bilirubin 
was absent, and no excess urobilinogen or urobilin 
was present. The cream was then applied also to the foot 
and the baby was allowed to go home. On the 10th day of 
treatment with this drug the mother noted the development 
of a diffuse rash on the baby’s skin but continued using the 
cream for a further 15 days, when she was again seen by us 
with a blotchy erythematous rash on the hands, feet, back 
and abdomen, and the mother said that the baby’s hair was 
beginning to fall out. The drug was stopped and the rash 
faded. It was obvious that there had been no arrest of the 
spread of the lesions on the arm and shoulder, and a new 
lesion had developed on the shoulder and also on the right 
thumb, presumably as a result of autoinoculation.

After this treatment the child was given 1 g. of anti-
vaccinal gamma-globulin (batch EPG 101) daily for two 
days and 1 g. 15 and 26 days later. When her serum was 
tested 11 days after the last dose of gamma-globulin it was 
found that the H.I. titre was only 1:5 and the serum gamma-
globulin had dropped to 0.38 g./100 ml.

When the lesions had been present for 201 days the effect 
of interferon was tried. This was kindly supplied by Dr. 
A. J. Beale, of Glaxo Laboratories Ltd., Stoke Poges, as 
cynomolgus monkey interferon batch 106 ACD/1st harvest.
It had a titre of 1:50 against an E.C.B.O.* virus (strain M 6) 
in monkey-kidney cells before filtration through a 0.45-μ 
membrane. Four ml. of this interferon was infiltrated intra-
cutaneously and subcutaneously by multiple injections 
around the spreading edge of one area of the lesion on the 
chest. During the next 10 days the lesion continued to 
spread, but at a considerably slower rate over the area of the skin 
where interferon had been injected as on the untreated skin.

In an attempt to try to obtain high levels of antibody we 
decided to give large doses of antivaccinal gamma-globulin 
and immune serum. Accordingly, 10 g. of antivaccinal 
gamma-globulin (batch EPG 138) was given by intra-
muscular injection over a period of five days, followed three 
days later by an intravenous transfusion of 400 ml. of 
pooled serum from two recently revaccinated colleagues.
The antibody levels and the gamma-globulin, which 
developed in the child’s serum are shown in Table II.

In spite of this amount of antibody and further mainten-
ance doses of gamma-globulin the lesions continued to 
spread on the chest and shoulder as seen in Fig. 2. The 
foot lesion showed little change, but the lesion on the thumb

*Enteric cytopathogenic bovine orphan virus.

<table>
<thead>
<tr>
<th>Day of Lesions</th>
<th>Procedure</th>
<th>Material Tested</th>
<th>Antibody Titres</th>
<th>Serum γ-Globulin (g./100 ml.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>212</td>
<td>Test 50 g.</td>
<td>Patient’s serum</td>
<td>5 640 3,200 0.47</td>
<td></td>
</tr>
<tr>
<td>216-220</td>
<td>100 g.</td>
<td>Patient’s serum</td>
<td>5 20 0.60</td>
<td></td>
</tr>
<tr>
<td>222</td>
<td>400 ml.</td>
<td>Donor’s serum</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>223</td>
<td>Test</td>
<td>Patient’s serum</td>
<td>300 80 &gt; 125</td>
<td></td>
</tr>
<tr>
<td>226</td>
<td>Test</td>
<td>Patient’s serum</td>
<td>100 40 &gt; 125</td>
<td></td>
</tr>
</tbody>
</table>

FIG. 2.—Vaccinal lesions 36 weeks after vaccination.

had extended beyond the interphalangeal joint and the 
nailbed was black.

On the 265th day of the lesions we decided to try the 
effect of N-methylisatin β-thiosemiacarbzone by mouth in 
dose of 250 mg. six-hourly for 14 days. After this treat-
ment the lesions continued to spread and the child now 
looked ill; her hair was thin, and the liver was hard 
and enlarged 3-5 cm. below the costal margin. The 
abdomen was enlarged and some free fluid was present. 
The white-cell count was 8,150/c.mm. and the lymphopenia 
was still present. Two weeks later she developed broncho-
pneumonia and died on the 302nd day after being 
vaccinated.

Discussion

Neutralizing antibody levels after primary vaccination 
are about 1:5 to 1:10 (A. W. Downie, personal com-
munication), yet our patient had no detectable antibody 
in spite of large areas of virus multiplication. The 
serum gamma-globulin was low in this child before 
treatment began and later fell to lower levels before 
being restored with large doses of gamma-globulin.

While the majority of children with hypogammaglobu-
linaeemia react normally to smallpox vaccination (Good 
and Varco, 1955; Kempe, 1960) some develop compli-
cations such as progressive vaccinia but survive after 
the administration of antivaccinal gamma-globulin. In 
others, as in our patient, the lesions continue to progress 
even after very high levels of neutralizing antibody (more 
than 1:125 in this patient) have been achieved. There

is thus a considerable amount of evidence which 
indicates that the presence of neutralizing antibody in 
the serum does not influence the progress of the 
cutaneous vaccinal lesions. These observations in 
humans have been confirmed by experiments in guinea-
pigs by Friedman and Baron (1961), who showed that 
in irradiated guinea-pigs in which no detectable antibody 
was present the recovery from vaccinia infections was 
as rapid as in normal animals.

Kempe (1960) suggested that in addition to humoral 
and cellular defence mechanism to limit the spread of vaccinia virus in the skin and that this might be delayed hypersensitivity. This hypothesis
was recently investigated by Turk, Allison, and Oxman (1962) in guinea-pigs. Their experiments showed that there was little difference in the quantity of virus which multiplied in animals devoid of circulating antibody with delayed hypersensitivity compared with normal animals, and suggested that the spread of vaccinia virus is normally limited by factors, other than antibody and delayed hypersensitivity, among which is interferon. Although vaccinia virus is sensitive to interferon (Andrews, 1961) there is nevertheless no evidence that the immune status which an individual develops after vaccination is due to an increased amount of interferon in his skin. Our failure to influence the progress of the lesions in our patient with interferon was perhaps due to the low titre of interferon available at the time, and interferon should certainly be tried in future cases of progressive vaccinia.

It is remarkable that the foot lesion remained static for nine months while the arm and thumb lesions progressed, yet in spite of an actively spreading edge the early arm lesions healed with little scarring.

The only occasion on which there was any apparent sign of remission in the patient was a few days after the fresh blood transfusion during a period of pyrexia. It is possible that this temporary remission may have been due to the transfer of a delayed type of hypersensitivity by the white cells in the donor’s blood. In any event it would seem that in future cases of progressive vaccinia, in addition to providing passive antibody, hypersensitivity to vaccinia might be induced by local injection of disrupted white cells or lymph-node suspensions from recently vaccinated individuals as suggested by Kempe (personal communication). The injection of viable immunologically competent cells may cause runt disease (Nisbet and Heslop, 1962), but this can be avoided by using white-cell extracts, which have been shown to be effective in transferring delayed type hypersensitivity to humans (Lawrence, 1960). Alternatively, sensitization might be induced by injecting vaccinia virus which had been inactivated by ultra-violet radiation or formalin.

We considered the possibility of surgical removal of the lesions in our patient but were dissuaded from this by the very slow progress of the condition, by the fact that the healed areas showed little scarring, and by the hope that the child might eventually overcome the infection.

There was no evidence that N-methylisatin β-thiosemicarbazone had any effect in controlling the progress of the disease or the cutaneous lesions, and the drug appeared to be toxic. This compound has caused no abnormalities when subjected to chronic toxicity tests in animals and no ill effects were observed in two adult human volunteers to whom the drug was given (Bauer and Goodwin, 1962), nor in an adult patient with leukaemia who developed progressive vaccinia (Davidson and Hayhoe, 1962).

Summary
The failure of large doses of antivaccinal gamma-globulin or N-methylisatin β-thiosemicarbazone to control the progress of infection in a fatal case of progressive vaccinia is described. Possible measures for treating further cases are discussed.

We thank Dr. R. Hall, who looked after this patient initially, and Dr. I. J. Carré for medical care during the first hospital admission. Our thanks are also due to Dr. J. C. McDonald, of the Public Health Laboratory Service, Colindale, for supplies of antivaccinal gamma-globulin, and to Mr. T. Macfarlane, F.I.M.L.T., for carrying out the serum electrophoresis. We are indebted to Dr. D. I. H. Simpson and Mr. D. Gay for donating immune blood.

Preliminary Communications
Ecema Vaccinatum Treated with N-Methylisatin β-Thiosemicarbazone

Much work has been done in recent years on the chemotherapy of the pox virus infections with isatin β-thiosemicarbazone and its derivatives. The compound itself will confer protection against death and development of symptoms in mice infected intracerebrally with 100,000 LD₅₀ of vaccinia virus (Bauer, 1955), and is equally effective against rabbit-pox virus (Bauer and Sheffield, 1959). A number of derivatives have been found with antiviral activity greater than that of isatin β-thiosemicarbazone itself (Bauer and Sadler, 1960a); of these, the N-ethyl derivative has been found to be active in mice infected with alastrim virus (Bauer and Sadler, 1960b), and the same compound and a number of others have been found to possess antiviral activity in mice infected with variola major virus (Bauer et al., 1962). The antiviral activities observed have in all cases been sufficiently great to indicate that some of these compounds might be of use in the specific chemotherapy of smallpox and vaccinia infection in man, and in the present communication an account is given of the use of N-methylisatin β-thiosemicarbazone (compound 33T57) in the treatment of eczema vaccinatum.

Case Report
The patient is a boy born on July 7, 1961, who had suffered from infantile eczema since the age of 6 weeks; at the age of 4½ months he was seen by a consultant dermatologist (Dr. I. B. MacMillan), and on treatment with a steroid-containing cream the lesions cleared. He was not vaccinated, but on January 18, 1962, both parents were successfully vaccinated, the mother having a primary vaccination, the father a secondary vaccinia with the immune accelerated reaction. On January 30 two small pustules appeared on the baby’s scalp; these were irritable, and the parents applied some of the steroid cream previously prescribed for the eczema. Within three days typical vaccinia lesions appeared all over the scalp and became